幼年皮肌炎诊断时内皮与炎症生物标志物谱反映临床异质性并预测治疗反应
研究在2个独立幼年皮肌炎队列(n=30和n=29)中检测39种内皮与炎症相关生物标志物,发现基于Galectin-9、CXCL10、TNFRII和Galectin-1的高水平聚类与更重病情相关,并可预测需要更强化治疗及更长治疗时间。
要点
- Galectin-9、CXCL10、TNFRII、Galectin-1高水平聚类与幼年皮肌炎病情严重度相关。
- 该聚类患者诊断后前3个月需要更强化治疗的风险更高(P=0.0437)。
- Galectin-9、CXCL10、TNFRII高水平可预测更长总治疗时间(P<0.05)。
核心结论
- 新发幼年皮肌炎基于血清生物标志物谱存在异质性,高Galectin-9、CXCL10、TNFRII和Galectin-1水平患者可能对常规治疗反应欠佳,或需更密切监测和/或更强化治疗。
研究设计与样本
- 在两个独立队列(n=30和n=29)的未治疗幼年皮肌炎患者血清中,用多重技术检测39种内皮细胞活化、内皮功能障碍和炎症相关生物标志物。
- 采用无监督层次聚类、多重比较校正的非参数检验及Kaplan-Meier检验联合Cox比例风险模型分析治疗持续时间,并用线印迹法检测肌炎特异性抗体(MSAs)。
主要发现
- 严重血管病变与可溶性细胞间黏附分子1低水平相关(Spearman's rho [rs]=0.465,P=0.0111),与endoglin高水平相关(rs=-0.67,P<0.0001)。
- 发现队列中无监督层次聚类得到2个不同患者聚类,较小聚类(聚类1;n=8)血清CXCL13、CCL19、galectin-9、CXCL10、肿瘤坏死因子受体II型(TNFRII)和galectin-1水平高(错误发现率<0.0001),且肌肉疾病严重度和整体疾病活动度更高(均P<0.05 vs 聚类2)。
- 验证队列中确认galectin-9、CXCL10、TNFRII和galectin-1血清水平与整体疾病活动度严重度相关(rs=0.40-0.52,P<0.05)。
- 依据4个确认的生物标志物分层,识别出严重症状患者聚类(占64.7%),该聚类患者诊断后前3个月需要更强化治疗的风险更高(P=0.0437 vs 其他聚类)。
- galectin-9、CXCL10和TNFRII高水平可预测更长总治疗时间(P<0.05),基于生物标志物的聚类与患者MSA血清型无明显相关性。
临床怎么用
- 诊断时检测Galectin-9、CXCL10、TNFRII和Galectin-1有助于识别可能对常规治疗反应欠佳、需更强化监测和/或治疗的幼年皮肌炎患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Juvenile dermatomyositis (DM) is a heterogeneous systemic immune-mediated vasculopathy. This study was undertaken to 1) identify inflammation/endothelial dysfunction-related biomarker profiles reflecting disease severity at diagnosis, and 2) establish whether such biomarker profiles could be used for predicting the response to treatment in patients with juvenile DM. METHODS: In total, 39 biomarkers related to activation of endothelial cells, endothelial dysfunction, and inflammation were measured using multiplex technology in serum samples from treatment-naive patients with juvenile DM from 2 independent cohorts (n = 30 and n = 29). Data were analyzed by unsupervised hierarchical clustering, nonparametric tests with correction for multiple comparisons, and Kaplan-Meier tests with Cox proportional hazards models for analysis of treatment duration. Myositis-specific antibodies (MSAs) were measured in the patients' serum using line blot assays. RESULTS: Severe vasculopathy in patients with juvenile DM was associated with low serum levels of intercellular adhesion molecule 1 (Spearman's rho [rs ] = 0.465, P = 0.0111) and high serum levels of endoglin (rs = -0.67, P < 0.0001). In the discovery cohort, unsupervised hierarchical clustering analysis of the biomarker profiles yielded 2 distinct patient clusters, of which the smaller cluster (cluster 1; n = 8) exhibited high serum levels of CXCL13, CCL19, galectin-9, CXCL10, tumor necrosis factor receptor type II (TNFRII), and galectin-1 (false discovery rate <0.0001), and this cluster had greater severity of muscle disease and global disease activity (each P < 0.05 versus cluster 2). In the validation cohort, correlations between the serum levels of galectin-9, CXCL10, TNFRII, and galectin-1 and the severity of global disease activity were confirmed (rs = 0.40-0.52, P < 0.05). Stratification of patients according to the 4 confirmed biomarkers identified a cluster of patients with severe symptoms (comprising 64.7% of patients) who were considered at high risk of requiring more intensive treatment in the first 3 months after diagnosis (P = 0.0437 versus other cluster). Moreover, high serum levels of galectin-9, CXCL10, and TNFRII were predictive of a longer total treatment duration (P < 0.05). The biomarker-based clusters were not evidently correlated with patients' MSA serotypes. CONCLUSION: Results of this study confirm the heterogeneity of new-onset juvenile DM based on serum biomarker profiles. Patients with high serum levels of galectin-9, CXCL10, TNFRII, and galectin-1 may respond suboptimally to conventional treatment, and may therefore benefit from more intensive monitoring and/or treatment.
引用
- Wienke J, Pachman LM, Morgan GA, et al. Endothelial and Inflammation Biomarker Profiles at Diagnosis Reflecting Clinical Heterogeneity and Serving as a Prognostic Tool for Treatment Response in Two Independent Cohorts of Patients With Juvenile Dermatomyositis. Arthritis Rheumatol. 2020. PMID: 32103637. doi:10.1002/art.41236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。